Skip to main content
DAEWON PHARMACEUTICAL CO.,LTD logo

DAEWON PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 003220 ISIN · KR7003220001 KO Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2019-02-22 Director's Dealing
Country KR South Korea
Listing KO 003220

About DAEWON PHARMACEUTICAL CO.,LTD

https://www.daewonpharm.com/eng

Daewon Pharmaceutical Co., Ltd., established in 1958, is a pharmaceutical company focused on improving human health. The company specializes in the development and manufacturing of prescription drugs and finished pharmaceutical products. Its portfolio includes a range of medications such as antipyretics, analgesics, and treatments for respiratory and cardiovascular conditions. Daewon Pharmaceutical maintains a strong commitment to research and development, with a strategic focus on New Chemical Entities (NCE) and Incrementally Modified Drugs (IMD) to provide advanced healthcare solutions.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서). This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading or changes in shareholdings by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-02-22 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Daewon Pharmaceutical. It details specific changes in share ownership for directors and related parties, including reasons like 'free share acquisition' (무상신주취득) and 'market purchase' (장내매수). This falls under the category of Major Shareholding Notification, as it tracks changes in significant ownership levels by insiders and major shareholders.
2019-02-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (DART system) to report insider trading or changes in share ownership by company directors and executives. Based on the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2019-02-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (Daewon Pharmaceutical) announcing a significant change in financial results (revenue or profit structure change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (KRX) for preliminary financial results before the final audit report is published. Since it provides key financial highlights and performance metrics rather than the full annual report or a simple publication notice, it falls under the 'Earnings Release' category.
2019-02-12 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 95% confidence The document is a regulatory disclosure from Daewon Pharmaceutical regarding its 'Compliance Program' (CP) operations, detailing past performance and future plans. This type of disclosure, which focuses on internal governance, ethics, and regulatory compliance programs, falls under the category of Governance Information (CGR) as it outlines the company's internal rules and compliance structure.
2019-01-31 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Daewon Pharmaceutical. It outlines the date, location, and agenda items (such as financial statement approval, dividend proposals, and board remuneration) for the upcoming Annual General Meeting. This document serves as the official solicitation and notification of the meeting, which falls under the Proxy Solicitation & Information Statement category.
2019-01-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.